Pumas

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products for the treatment of various forms of cancer. The company's lead product, Nerlynx (neratinib), is an oral, irreversible tyrosine kinase inhibitor approved for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer. Beyond its commercial success, Puma is aggressively expanding its pipeline by investigating neratinib in several other indications, including metastatic breast cancer and non-small cell lung cancer. Additionally, the company is developing alisertib, an Aurora kinase A inhibitor, targeting small cell lung cancer and breast cancer. Puma Biotechnology focuses on precision medicine, aiming to address significant unmet needs in oncology through targeted therapeutic interventions.